^
    Back
    Association details:
    Biomarker:BRAF wild-type
    Cancer:Cutaneous Melanoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    J Clin Oncol
    Title:

    Systemic Therapy for Melanoma: ASCO Guideline

    Published date:
    03/31/2020
    Excerpt:
    For patients with BRAF wild-type unresectable/metastatic cutaneous melanoma, the following treatment options should be offered (in no particular order): ipilimumab plus nivolumab followed by nivolumab OR nivolumab OR pembrolizumab...(Type: Evidence based, benefits outweigh harms; Evidence quality: High; Strength of recommendation: Strong).
    DOI:
    10.1200/JCO.20.00198